Who is in your network?

Alzheimer’s Therapeutics Market Size, Forecast to 2033 | FMI

In 2023, the worldwide Alzheimer's therapeutics market is poised to reach a valuation of US$ 3,052.3 million. Anticipating a robust growth trajectory, the demand for Alzheimer's therapeutics is expected to surge at a notable CAGR of 9.2%, aiming for an impressive US$ 7,359.7 million by the year 2033.

Alzheimer’s Therapeutics is the most common reason for progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer’s Therapeutics worldwide emphasizing the necessity for developing an effective treatment. According to Alzheimer’s Association, in 2016, an estimated 5.4 million Americans of all ages have Alzheimer’s disease.

The mortality rates due to Alzheimer’s Therapeutics are quite high. Between 2000 and 2013, deaths due to heart disease, stroke and prostate cancer decreased by 14%, 23% and 11%, respectively, while deaths from ALZHEIMER’S THERAPEUTICS increased by 71% in the U.S. Similarly, According to Alzheimer’s Therapeutics International in 2015, there are an estimated 46.8 million people worldwide living with dementia and is further expected to grow in future. Thus, there is an increase in the demand for Alzheimer’s therapeutics and diagnostics worldwide.

Download the free PDF of this Report Now @ https://www.futuremarketinsigh....ts.com/reports/sampl

Population ageing across the globe is a major factor driving the market for Alzheimer’s therapeutics and diagnostics. Rising life expectancy is contributing to quick increases in the number of the aged population. In addition, is associated with increased prevalence of chronic diseases like dementia.

Therapies for alzheimer’s therapeutics offer temporary and uncertain improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease Alzheimer’s Therapeutics cement. Thus, the magnitude of the affected population and the lack of suitable and effective treatment offers an incredible opportunity for drug manufacturers.

However, the identification of the primary reasons and mechanisms involved in alzheimer’s therapeutics is limited. Drug manufacturers have been unable to validate the significant clinical benefits of treatment for numerous new compounds due to strict regulations. One of the significant trends observed in this market is the collaboration of the existing players.

Precisely, diagnostic technology companies are carefully trying to bring about effective biomarker technologies to support and improve the drug development process for potential drug candidates, which is further expected to propel the demand.

Developing countries are expected to offer lucrative opportunities for this market. According to Alzheimer’s Therapeutics International in 2015, 58% of people with dementia live in developing countries, but by 2050 this will rise to 68%. The fastest growth in the elderly population is taking place in China, India, and their south Asian and western Pacific region.

According to World Alzheimer Report in 2015, regional estimations of dementia prevalence in people aged 60 years and over vary from 4.6% in Central Europe to 8.7% in North Africa and the Middle East, however, all other regional estimates fall in a relatively between 5.6% and 7.6%.

A list of Key Players Covered in the Alzheimer’s Therapeutics Market are:

AbbVie, Inc.

Teva Pharmaceuticals Ltd.

Eisai Co., Ltd.

Janssen Pharmaceuticals, Inc. (Johnson & Johnson)

Novartis AG

Zydus Lifesciences Ltd (CADILA)

Sun Pharmaceutical Industries Ltd.

Dr. Reddy’s Laboratories Ltd

Aurobindo Pharma Ltd

Amneal Pharmaceuticals Inc.

Macleods Pharmaceuticals Ltd.

Viatris Inc.

Lupin Ltd

Cipla Ltd.

Torrent pharmaceuticals ltd.

Unichem laboratories ltd

Lannett Inc.

Key Market Segments Covered in Alzheimer’s Therapeutics Industry Research

By Drug Name:

Donepezil

Rivastigmine

Memantine

Galantamine

Manufactured a combination of memantine and donepezil

By Drug Class:

Cholinesterase Inhibitors

NMDA Receptor Antagonists

Manufactured Combination

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Drug Stores

Online Pharmacies